DRUG DO-OVER: Johnson & Johnson is taking a second shot at getting U.S. approval to market anticlotting drug Xarelto for two additional uses.
THE HISTORY: This summer, the Food and Drug Administration rejected one of those applications and J&J withdrew the other. J&J has now submitted new data from a huge Xarelto study concluded last year.
THE MARKET: Xarelto is approved for reducing blood clot risk after knee or hip replacement surgery and lowering stroke risk in patients with an irregular heartbeat. It competes with one drug in a new generation of blood thinners, Pradaxa. Another, Eliquis, could be approved.
